¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Asymptomatic human immuno- deficiency virus"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • Cremean hemorrhagic fever virus
    Å©¸®¹Ì¾Æ ÃâÇ÷¿­¹ÙÀÌ·¯½º
  • DNA oncogenic virus
    DNA Á¾¾ç¹ÙÀÌ·¯½º
  • DNA virus
    DNA¹ÙÀÌ·¯½º
  • DNA oncogenic virus
    DNA Á¾¾ç¹ÙÀÌ·¯½º
  • DNA virus
    DNA ¹ÙÀÌ·¯½º
  • DNA-containing virus
    DNA(Æ÷ÇÔ)¹ÙÀÌ·¯½º.
  • Dengue virus
    µ­±â ¹ÙÀÌ·¯½º
  • EB virus
    EB¹ÙÀÌ·¯½º
  • ECHO virus =enteric cytopathogenic dog or p han v.
    ¿¡ÄÚ¹ÙÀÌ·¯½º.
  • ECHO virus infection
    ¿¡ÄÚ¹ÙÀÌ·¯½º°¨¿°.
  • ECHO virus infection
    ¿¡ÄÚ¹ÙÀÌ·¯½º°¨¿°.
  • Eastern equine encephalitis virus
    µ¿ºÎ¸»³ú¿°¹ÙÀÌ·¯½º
  • Eastern equine encephalitis virus
    µ¿ºÎ ¸» ³ú¿° ¹ÙÀÌ·¯½º
  • Ebola virus
    ¿¡º¼¶ó¹ÙÀÌ·¯½º
  • Ebola virus
    ¿¡º¼¶ó ¹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • antibody deficiency syndrome
    Ç×ü°áÇÌÁõÈıº(ù÷ô÷ÌÀù¹ñøý¦ÏØ).
  • antitrypsin deficiency
    Çׯ®¸³½Å°áÇÌ
  • apolipoprotein C-Il deficiency
    ¾ÆÆ÷Áö´Ü¹é C-II °áÇÌ
  • apolipoprotein b, deficiency
    ¾ÆÆ÷¸®Æ÷´Ü¹éB°áÇÌÁõ(¡­Ó±ÛÜ¡­ÌÀù¹ñø)
  • arylsulfatase a deficiency
    ¾Æ¸±¼³ÆÄŸÁ¦ A °áÇÌÁõ(¡­ÌÀù¹ñø)
  • aspartylglycosamine amide hydrolase, deficiency
    Aspartylglycosamine amide hydrolase°áÇÌ(¡­ÌÀù¹)
  • biotin-deficiency
    ¹ÙÀÌ¿Àƾ°áÇÌÁõ (¡­ÌÀù¹ñø).
  • biotin-deficiency
    ¹ÙÀÌ¿Àƾ°áÇÌÁõ (¡­ÌÀù¹ñø)
  • brancher enzyme deficiency
    ºÐÁöÈ¿¼Ò°áÇÌ(Áõ)
  • brancher enzyme deficiency
    ºÐÁöÈ¿¼Ò°áÇÌ(¡­ý£áÈÌÀù¹).
  • c inhibitor deficiency
    º¸Ã¼ ÀúÁöÀÎÀÚ °áÇÌÁõ(ÜÍô÷îÁò­ì×í­ÌÀù¹ñø)
  • c3 deficiency
    C3 °áÇÌÁõ (¡­ÌÀù¹ñø)
  • carnitine palmitoyl transferase, deficiency
    Carnitine palmitoyl transferase, deficiency
  • cell adhesion molecular deficiency
    ¼¼Æ÷À¯ÂøºÐÀÚ°áÇÌ
  • cell deficiency (aganglionic megacolon)
    ¼¼Æ÷ÀÌÁÖ°áÇÌ (¹«½Å°æÀýÁÖ¸§Ã¢ÀÚ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
RIA Radio-Immuno-Assay; ¹æ»ç ¸é¿ª¹ý
RIBA Recombinant Immuno-Blot Assay
RIPA Radio-Immuno(= Immune)-Precipitation(Precipitin) Assay
RIST Radio-Immuno-Sorbent Test
VZIG Varicella Zoster Immuno-Globulin; ¼öµÎ´ë»ó Æ÷Áø ¸é¿ª ±Û·ÎºÒ¸°
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
ATD 1-antitrypsin deficiency
AMD Acid maltase deficiency
AIDS Acquire Immune Deficiency Syndrome
AIDS Acquired Immune Deficiency Disease Syndrome
alpha1ATD Alpha-1-antitrypsin deficiency
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • monkey pox virus
    ¿ø¼þÀÌ Æø½º ¹ÙÀÌ·¯½º
  • neonatal calf diarrhea corona virus
    ½Å»ý¾Æ ¼³»ç Äڷγª ¹ÙÀÌ·¯½º
  • neurotropic virus
    Çâ½Å°æ¼º ¹ÙÀÌ·¯½º
  • oral herpes simplex virus
    ±¸°­ ´Ü¼ø Æ÷Áø ¹ÙÀÌ·¯½º
  • papilloma virus
    À¯µÎÁ¾ ¹ÙÀÌ·¯½º
    Àΰ£°ú µ¿¹°¿¡¼­ À¯µÎÁ¾ ¶Ç´Â »ç¸¶±Í¸¦ ÀÏÀ¸Å°´Â ¹ÙÀÌ·¯½ºÀÇ ¹«¸®. ÆÄº¸¹Ù ¹ÙÀÌ·¯½º°ú¿¡ ¼ÓÇÑ´Ù. º´ÀÇ ÀüÆÄ´Â º¸Åë ȯÀÚ¿ÍÀÇ Á÷Á¢ Á¢ÃËÀ̳ª ÀÚ°¡ Á¢Á¾¿¡ ÀÇÇÑ´Ù. »ç¸¶±Í´Â ÀϹÝÀûÀ¸·Î ÀÚÀ²¼º º´º¯À¸·Î 6°³¿ù ³»Áö 2³â ³»¿¡ ÀÚ¿¬ ¼Ò½ÇµÈ´Ù.
  • parainfluenza 1 virus
    Á¦1Çü ÆÄ¶ó ÀÎÇ÷翣ÀÚ ¹ÙÀÌ·¯½º
  • parainfluenza 3 virus
    Á¦3Çü ÆÄ¶ó ÀÎÇ÷翣ÀÚ ¹ÙÀÌ·¯½º
  • plant virus
    ½Ä¹° ¹ÙÀÌ·¯½º
  • polyoma virus
    Æú¸®¿À¸¶ ¹ÙÀÌ·¯½º
  • rabies virus
    ±¤°ßº´ ¹ÙÀÌ·¯½º
  • recurrent herpes simplex virus infection
    Àç¹ß¼º ´Ü¼ø Æ÷Áø ¹ÙÀÌ·¯½º °¨¿°
  • rhabdo virus
    ¶óºêµµ ¹ÙÀÌ·¯½º
  • RNA virus
    ¸®º¸ ¹ÙÀÌ·¯½º
  • simian virus
    ¿ø¼þÀÌ ¹ÙÀÌ·¯½º
  • slow virus
    ½½·Î¿ì ¹ÙÀÌ·¯½º
    ¼¼Æ÷ ¼Ó¿¡ Àå±â°£ Àáº¹ÇØ ÀÖ´Ù°¡ ¾î¶² °è±â·Î »ýü¿¡ º´º¯À» ÀÏÀ¸Å²´Ù°í »ý°¢µÇ´Â ¹ÙÀÌ·¯½º. ¹ßº´ÀÌ Áö¹ß¼ºÀ̰í ÁøÇ༺À̶ó´Â Á¡¿¡¼­ 1954³â¿¡ ½Ã±¸¸£µå¼ÕÀÌ Á¦Ã¢ÇÑ °³³äÀÌ´Ù. Àẹ±â°¡ 2¡­3³â, ±ä °ÍÀº 6¡­7³âÀ̸ç Çѹø ¹ßº´ÇÏ¸é ¸¸¼º ÁøÇ༺ °æ°ú¸¦ ¹â´Â´Ù. ÀÌ °¨¿°ÁõÀÌ ÁÖ¸ñÀ» ¹Þ°Ô µÈ °ÍÀº 57³â ¹Ì±¹ÀÇ D.C. °¡À̵༽
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
coronavirus, human A species of coronavirus causing respiratory and enteric diseases in humans.
(12 Dec 1998)
corpus luteum deficiency syndrome <syndrome> Functional disturbances caused by insufficient ovarian luteinization; reflected by inadequate luteal phase endometrial response.
(05 Mar 2000)
polyendocrine deficiency syndrome <syndrome> Polyglandular deficiency syndrome, associated pathologic dysfunction of several endocrine glands, as in Schmidt's syndrome.
(05 Mar 2000)
myophosphorylase deficiency glycogenosis Glycogenosis due to muscle glycogen phosphorylase deficiency, resulting in accumulation of glycogen of normal chemical structure in muscle.
Synonym: McArdle's disease, McArdle's syndrome, McArdle-Schmid-Pearson disease, myophosphorylase deficiency glycogenosis.
(05 Mar 2000)
potassium deficiency A condition due to decreased dietary intake of potassium, as in starvation or failure to administer in intravenous solutions, or to gastrointestinal loss in diarrhoea, chronic laxative abuse, vomiting, gastric suction, or bowel diversion. Severe potassium deficiency may produce muscular weakness and lead to paralysis and respiratory failure. Muscular malfunction may result in hypoventilation, paralytic ileus, hypotension, muscle twitches, tetany, and rhabomyolysis. Nephropathy from potassium deficit impairs the concentrating mechanism, producing polyuria and decreased maximal urinary concentrating ability with secondary polydipsia. (merck manual, 16th ed)
(12 Dec 1998)
hageman factor deficiency A deficiency of a specific blood clotting factor (XII) that may be genetic or acquired. Administration of heparin or severe liver disease may result in factor XII (Hageman factor) deficiency. There are usually no symptoms associated with this deficiency, but there may be symptoms of mild blood loss in some cases. Treatment is generally unnecessary. Individuals should be cautioned against the use of medications (for example aspirin, warfarin, heparin) with anticoagulant activity, due to risk of exaggerated effects.
(27 Sep 1997)
health and human services See HHS.
(12 Dec 1998)
hepatitis, viral, human Viral hepatitis in man.
(12 Dec 1998)
hepatophosphorylase deficiency glycogenosis Glycogenosis due to hepatic glycogen phosphorylase deficiency, resulting in accumulation of glycogen of normal chemical structure in liver and leukocytes.
Synonym: hepatophosphorylase deficiency glycogenosis, Hers' disease.
(05 Mar 2000)
protein c deficiency Protein C is a protein in plasma that enters into the cascade of biochemical events leading to the formation of a clot. Deficiency of protein c results in thrombotic (clotting) disease and excess platelets with recurrent thrombophlebitis (inflammation of the vein that occurs when a clot forms). The clot can break loose and travel through the blood stream (thromboembolism) to the lungs causing a pulmonary embolism, brain causing a stroke (cerebrovascular accident), heart causing an early heart attack, skin causing what in the newborn is called neonatal purpura fulminans, the adrenal gland causing haemorrhage with abdominal pain, abnormally low blood pressure (hypotension), and salt loss. Protein c deficiency is due to possession of one gene (heterozygosity) in chromosome band 2q13-14. The possession of two such genes (homozygosity) is usually lethal.
(12 Dec 1998)
protein deficiency A nutritional condition produced by a deficiency of proteins in the diet, characterised by adaptive enzyme changes in the liver, increase in amino acid synthetases, and diminution of urea formation, thus conserving nitrogen and reducing its loss in the urine. Growth, immune response, repair, and production of enzymes and hormones are all impaired in severe protein deficiency. Protein deficiency may also arise in the face of adequate protein intake if the protein is of poor quality (i.e., the content of one or more amino acids is inadequate and thus becomes the limiting factor in protein utilization).
(12 Dec 1998)
protein s deficiency An autosomal dominant disorder showing decreased levels of plasma protein s antigen or activity, associated with venous thrombosis and pulmonary embolism. Protein s is a vitamin k-dependent plasma protein that inhibits blood clotting by serving as a cofactor for activated protein c (also a vitamin k-dependent protein), and the clinical manifestations of its deficiency are virtually identical to those of protein c deficiency. Treatment with heparin for acute thrombotic processes is usually followed by maintenance administration of coumarin drugs for the prevention of recurrent thrombosis.
(12 Dec 1998)
prothrombin deficiency A congenital or acquired disorder of blood clotting where there is a deficiency of factor II (prothrombin), one of 20 necessary plasma proteins for normal blood coagulation. Acquired factor II deficiency may result from vitamin K deficiency, severe liver disease and anticoagulant drugs.
Symptoms include abnormal bleeding, nosebleeds, abnormal menstrual bleeding, easy bruising and umbilical cord bleeding at birth. Treatment involves the infusion of fresh frozen plasma. Vitamin K may be administered in select cases.
(27 Sep 1997)
proximal femoral focal deficiency A congenital defect in which variable portions of the upper end of the femur are reduced or absent.
(05 Mar 2000)
pseudocholinesterase deficiency An autosomal dominant disorder manifested by exaggerated responses to drugs ordinarily hydrolyzed by serum pseudocholinesterase (e.g., succinylcholine); believed to entail production of a variant enzyme that is less active than the normal enzyme in hydrolyzing appropriate substrates, but also abnormally resistant to the effects of anticholinesterases.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á